AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Clinical trial NCT05198960 · RECRUITING

Trial details

NCT number: NCT05198960
Sponsor: University Hospital, Brest
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Polycythemia Vera Essential Thrombocythemia Prefibrotic/Early Primary Myelofibrosis JAK2 V617F High-risk Patients

Start date: 2022-07-13
Primary completion: 2027-07-13
Enrollment: 1308

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.